دورية أكاديمية
أعرض في EDS

Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond.

التفاصيل البيبلوغرافية
العنوان: Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond.
المؤلفون: Steiner G; Division of Rheumatology, Department of Internal Medicine III; Medical University of Vienna.; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria., Toes REM; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: Current opinion in rheumatology [Curr Opin Rheumatol] 2024 May 01; Vol. 36 (3), pp. 217-224. Date of Electronic Publication: 2024 Feb 26.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams And Wilkins Country of Publication: United States NLM ID: 9000851 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-6963 (Electronic) Linking ISSN: 10408711 NLM ISO Abbreviation: Curr Opin Rheumatol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : Lippincott Williams And Wilkins
Original Publication: Philadelphia, PA : Current Science, c1989-
مواضيع طبية MeSH: Arthritis, Rheumatoid*/drug therapy , Rheumatoid Factor*, Humans ; Autoantibodies ; Immunoglobulin A ; Immunoglobulin G
مستخلص: Purpose of Review: RA is characterized by the presence of autoantibodies among which rheumatoid factors (RFs) and antimodified protein antibodies (AMPA) are serological hallmarks of the disease. In recent years, several novel insights into the biology, immunogenetics and clinical relevance of these autoantibodies have been obtained, which deserve to be discussed in more detail.
Recent Findings: RFs from RA patients seem to target distinct epitopes which appear to be quite specific for RA. Determination of immunoglobulin A (IgA) isotypes of RF and anticitrullinated protein antibodies (ACPA) may provide prognostic information because their presence is associated with reduced therapeutic responses to TNF inhibitors. Furthermore, IgA levels are increased in RA patients and IgA immune complexes are more potent than immunoglobulin G (IgG) complexes in inducing NET formation. Concerning AMPAs, investigations on variable domain glycosylation (VDG) revealed effects on antigen binding and activation of autoreactive B cells. Studies on pathogenetic involvement of ACPA suggest Janus-faced roles: on the one hand, ACPA may be involved in joint destruction and pain perception while on the other hand protective anti-inflammatory effects may be attributed to a subset of ACPAs.
Summary: The autoimmune response in RA is extremely complex and still far from being fully understood. Antibodies are not only valuable diagnostic biomarkers but also seem to play pivotal roles in the pathophysiology of RA.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 2020; 110:102392.
Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings. Clin Rev Allergy Immunol 2022; 63:138–151.
Trouw LA, Rispens T, Toes REM. Beyond citrullination: other posttranslational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol 2017; 13:331–339.
Thiele GM, Duryee MJ, Anderson DR, et al. Malondialdehyde-acetaldehyde adducts and antimalondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol 2015; 67:645–655.
van den Beukel MD, van Wesemael TJ, Hoogslag ATW, et al. Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open 2023; 9:e003480.
De Stefano L, D’Onofrio B, Gandolfo S, et al. Seronegative rheumatoid arthritis: one year in review. Clin Exp Rheumatol 2023; 41:554–564.
Steiner G, Van Hoovels L, Csige D, et al. Should ACR/EULAR criteria be revised changing the RF and ACPA scores? Autoimmun Rev 2023; 103421.
Sohrabian A, Mathsson-Alm L, Hansson M, et al. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis. Ann Rheum Dis 2018; 77:1345–1353.
Li Y, Tong D, Liang P, et al. Cartilage-binding antibodies initiate joint inflammation and promote chronic erosive arthritis. Arthritis Res Ther 2020; 22:120.
Li Q, Li Y, Liang B, et al. Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage. Arthritis Res Ther 2022; 24:257.
Verheul MK, Bohringer S, van Delft MAM, et al. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals. Arthritis Rheumatol 2018; 70:1721–1731.
Brink M, Hansson M, Mathsson-Alm L, et al. Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. Arthritis Res Ther 2016; 18:43.
Motta F, Bizzaro N, Giavarina D, et al. Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open 2023; 9:e002817.
Van Hoovels L, Vander Cruyssen B, Sieghart D, et al. IgA rheumatoid factor in rheumatoid arthritis. Clin Chem Lab Med 2022; 60:1617–1626.
Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66:302–307.
Sieghart D, Konrad C, Swiniarski S, et al. The diagnostic and prognostic value of IgG and IgA anticitrullinated protein antibodies in patients with early rheumatoid arthritis. Front Immunol 2022; 13:1096866.
Oskam N, Ooijevaar-De Heer P, Kos D, et al. Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity. Ann Rheum Dis 2023; 82:945–956.
Steffen U, Koeleman CA, Sokolova MV, et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun 2020; 11:120.
Gimpel AK, Maccataio A, Unterweger H, et al. IgA complexes induce neutrophil extracellular trap formation more potently than IgG complexes. Front Immunol 2021; 12:761816.
Derksen V, Allaart CF, Van der Helm-Van Mil AHM, et al. In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. Rheumatology (Oxford) 2022; 62:407–416.
Pertsinidou E, Saevarsdottir S, Manivel VA, et al. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation. Ann Rheum Dis 2023; ard-2023-224728. [Online ahead of print].
Kissel T, Reijm S, Slot LM, et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other posttranslational modifications. Ann Rheum Dis 2020; 79:472–480.
Sahlstrom P, Hansson M, Steen J, et al. Different hierarchies of anti-modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol 2020; 72:1643–1657.
Ge C, Xu B, Liang B, et al. Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheumatol 2019; 71:210–221.
Ge C, Holmdahl R. The structure, specificity and function of anticitrullinated protein antibodies. Nat Rev Rheumatol 2019; 15:503–508.
Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108:17372–17377.
Juarez M, Bang H, Hammar F, et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 2016; 75:1099–1107.
Studenic P, Alunno A, Sieghart D, et al. Presence of antiacetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021; 13:.
Rombouts Y, Willemze A, van Beers JJ, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 2016; 75:578–585.
Vergroesen RD, Slot LM, Hafkenscheid L, et al. B-cell receptor sequencing of anticitrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation. Ann Rheum Dis 2018; 77:956–958.
Hafkenscheid L, Bondt A, Scherer HU, et al. Structural analysis of variable domain glycosylation of anti-citrullinated protein antibodies in rheumatoid arthritis reveals the presence of highly sialylated glycans. Mol Cell Proteomics 2017; 16:278–287.
Hafkenscheid L, de Moel E, Smolik I, et al. N-Linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheumatol 2019; 71:1626–1633.
Kissel T, van Wesemael TJ, Lundquist A, et al. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Ann Rheum Dis 2022; 81:141–143.
Koers J, Sciarrillo R, Derksen NIL, et al. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J Allergy Clin Immunol 2023; 151:1646–1654.
Kissel T, Ge C, Hafkenscheid L, et al. Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Sci Adv 2022; 8:eabm1759.
Wigerblad G, Bas DB, Fernades-Cerqueira C, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis 2016; 75:730–738.
Krishnamurthy A, Joshua V, Haj Hensvold A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 2016; 75:721–729.
Amara K, Steen J, Murray F, et al. Retraction: Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2019; 216:245.
Toes R, Pisetsky DS. Pathogenic effector functions of ACPA: where do we stand? Ann Rheum Dis 2019; 78:716–721.
Krishnamurthy A, Circiumaru A, Sun J, et al. Combination of two monoclonal anti-citrullinated protein antibodies induced tenosynovitis, pain, and bone loss in mice in a peptidyl arginine deiminase-4-dependent manner. Arthritis Rheumatol 2023; 75:164–170.
Jurczak A, Sandor K, Bersellini-Farinotti A, et al. Insights into FcgammaR involvement in pain-like behavior induced by an RA-derived antimodified protein autoantibody. Brain Behav Immun 2023; 113:212–227.
Jurczak A, Delay L, Barbier J, et al. Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization. Pain 2022; 163:1542–1559.
Chirivi RGS, van Rosmalen JWG, van der Linden M, et al. Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases. Cell Mol Immunol 2021; 18:1528–1544.
He Y, Ge C, Moreno-Giro A, et al. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis. Nat Commun 2023; 14:691.
Raposo B, Afonso M, Israelsson L, et al. Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development. Ann Rheum Dis 2023; 82:724–726.
Gomez AM, Brewer RC, Moon JS, et al. Anti-citrullinated protein antibodies with multiple specificities ameliorate collagen antibody-induced arthritis in a time-dependent manner. Arthritis Rheumatol 2023; 76:181–191.
van der Linden M, Kumari S, Montizaan D, et al. Anticitrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases. MAbs 2023; 15:2281763.
Kristyanto H, Blomberg NJ, Slot LM, et al. Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. Sci Transl Med 2020; 12:eaaz5327.
Reijm S, Kwekkeboom JC, Blomberg NJ, et al. Autoreactive B cells in rheumatoid arthritis include mainly activated CXCR3+ memory B cells and plasmablasts. JCI Insight 2023; 8:e172006.
Brewer RC, Lanz TV, Hale CR, et al. Oral mucosal breaks trigger anticitrullinated bacterial and human protein antibody responses in rheumatoid arthritis. Sci Transl Med 2023; 15:eabq8476.
Kardava L, Rachmaninoff N, Lau WW, et al. Early human B cell signatures of the primary antibody response to mRNA vaccination. Proc Natl Acad Sci USA 2022; 119:e2204607119.
Van Hoovels L, Studenic P, Sieghart D, et al. J Transl Autoimmun 2022; 5:100142.
Van Hoovels L, Studholme L, Vander Cruyssen B, et al. Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Ann Rheum Dis 2022; 81:1379–1384.
Van Hoovels L, Vander Cruyssen B, Sieghart D, et al. Multicentre study to improve clinical interpretation of rheumatoid factor and anticitrullinated protein/peptide antibodies test results. RMD Open 2022; 8:.
Huang F, Liu X, Cheng Y, et al. Antibody to peptidoglycan recognition protein (PGLYRP)-2 as a novel biomarker in rheumatoid arthritis. Clin Exp Rheumatol 2021; 39:988–994.
Li K, Mo W, Wu L, et al. Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2021; 80:739–747.
Milchram L, Fischer A, Huber J, et al. Functional analysis of autoantibody signatures in rheumatoid arthritis. Molecules 2022; 27:1452.
Lonnblom E, Leu Agelii M, Sareila O, et al. Autoantibodies to disease-related proteins in joints as novel biomarkers for the diagnosis of rheumatoid arthritis. Arthritis Rheumatol 2023; 75:1110–1119.
Reed E, Hedstrom AK, Hansson M, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther 2020; 22:170.
Ronnelid J, Hansson M, Mathsson-Alm L, et al. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis 2018; 77:203–211.
Sieghart D, Platzer A, Studenic P, et al. Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis. Front Immunol 2018; 9:876.
المشرفين على المادة: 0 (Autoantibodies)
0 (Immunoglobulin A)
0 (Immunoglobulin G)
9009-79-4 (Rheumatoid Factor)
تواريخ الأحداث: Date Created: 20240227 Date Completed: 20240325 Latest Revision: 20240703
رمز التحديث: 20240703
مُعرف محوري في PubMed: PMC11139241
DOI: 10.1097/BOR.0000000000001006
PMID: 38411194
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-6963
DOI:10.1097/BOR.0000000000001006